News
SNGX
1.150
0.00%
0.000
Weekly Report: what happened at SNGX last week (0406-0410)?
Weekly Report · 2d ago
Soligenix publishes corporate presentation highlighting late-stage rare disease drug pipeline
Reuters · 04/08 20:55
Weekly Report: what happened at SNGX last week (0330-0403)?
Weekly Report · 04/06 09:15
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy
TipRanks · 04/02 16:00
Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial
TipRanks · 04/02 12:03
Soligenix Announces Publication Of Comparability Study Results Evaluating HyBryte Versus Valchlor For Treatment Of Cutaneous T-Cell Lymphoma In Oncology And Therapy
Benzinga · 04/02 11:33
Soligenix says HyBryte beats Valchlor in small cutaneous T-cell lymphoma study
Reuters · 04/02 11:31
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
PR Newswire · 04/02 11:30
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
TipRanks · 04/01 16:30
Soligenix Q4 EPS $(0.29) Beats $(0.56) Estimate
Benzinga · 04/01 05:20
Soligenix FY25 net loss widens 34% to $11.1 million; revenue drops to no revenue
Reuters · 03/31 20:08
Soligenix GAAP EPS of -$2.14 beats by $0.01
Seeking Alpha · 03/31 11:32
SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND YEAR END 2025 FINANCIAL RESULTS
Reuters · 03/31 11:30
Weekly Report: what happened at SNGX last week (0323-0327)?
Weekly Report · 03/30 09:15
Soligenix publishes corporate presentation; pipeline targets rare diseases with ~$2 billion in potential global annual sales
Reuters · 03/26 19:57
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
TipRanks · 03/26 16:00
Soligenix Secures EU Orphan Drug Status For Rare Disease Treatment, Designation Provides 10-Year Market Exclusivity And Development Support
Benzinga · 03/26 11:36
Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease
TipRanks · 03/26 11:36
Soligenix shares rise; European Commission grants orphan drug designation for SGX945 in Behçet's disease
Reuters · 03/26 11:31
More
Webull provides a variety of real-time SNGX stock news. You can receive the latest news about Soligenix Inc through multiple platforms. This information may help you make smarter investment decisions.
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).